SAN DIEGO, March 13, 2019 /PRNewswire/ -- Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor ...
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers In all, 142 (95%) of 150 questionnaires were completed by 38 ...
BEAVERTON, Ore., Sept. 16, 2021 /PRNewswire/ -- Tektronix, Inc., a leading worldwide provider of test and measurement solutions, today released KTE V7.1 software for the Keithley S530 Series ...
Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer ...
REDWOOD CITY, Calif., Feb. 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced the U.S. commercial launch of the Oncotype DX ® AR-V7 Nucleus Detect™ test. The first and only ...
SAN DIEGO and REDWOOD CITY, Calif., March 30, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative ...
Genomic Health, Inc.GHDX recently inked an exclusive deal with private diagnostic provider Epic Sciences to market and sell the latter's liquid biopsy test - AR-V7. Notably, the test will be available ...
This study used a blood test to look for a biomarker called AR-V7. This was to help doctors work out the best treatment for prostate cancer that had spread to other parts of the body. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback